Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults (REHAB-1)

NCT06783114 is registered in ClinicalTrials.gov with Chongqing Claruvis Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06783114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06783114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults (REHAB-1)
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 14, 2024
Completion date
September 30, 2026
Enrollment
254 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

upper limb spasticity